Ligand's Partner Travere Secures Full FDA Approval for FILSPARI, Reinforcing Key Royalty Driver

What happened

Ligand Pharmaceuticals announced that its partner Travere Therapeutics received full FDA approval for FILSPARI® (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), making it the first and only approved medicine for this rare kidney disorder. Ligand holds a 9% royalty on worldwide net sales of FILSPARI, which is a critical component of its royalty revenue stream. According to the DeepValue master report, LGND's stock at $198.58 already prices in a successful 2026 royalty step-up to $200M–$225M, with FILSPARI and Ohtuvayre as the primary growth drivers. The report emphasizes that forward returns depend on confirmatory partner datapoints, particularly FILSPARI sustaining a ~$100M+ quarterly sales run-rate and patient start forms (PSFs) holding near 900, as seen in 4Q25. While this approval reduces regulatory risk, the high valuation multiples (78.9x P/E, 103.1x EV/EBITDA) mean investors must still await proof of sustained demand to avoid a potential multiple reset.

Implication

The approval solidifies FILSPARI's market position, potentially accelerating Ligand's royalty growth from this asset. However, with LGND trading at 78.9x P/E and 103.1x EV/EBITDA, the stock embeds high expectations for FILSPARI to hit a $100M+ quarterly run-rate, as outlined in the DeepValue report. Investors must monitor Travere's upcoming quarterly updates for PSFs and net sales to ensure alignment with the base case scenario. Any shortfall could trigger a guidance miss, leading to multiple compression given LGND's concentrated reliance on FILSPARI and Ohtuvayre. Therefore, despite the positive news, the risk-reward remains unfavorable without a pullback to ~$175 or stronger evidence of sustained demand in 1H26.

Thesis delta

The FDA approval for FILSPARI in FSGS is a confirmatory event that aligns with the bullish assumptions in the DeepValue report, but it does not materially shift the investment thesis. The core thesis remains unchanged: LGND's valuation requires proof of sustained FILSPARI sales and Ohtuvayre visibility over the next 3-6 months. Investors should continue to base decisions on upcoming partner datapoints rather than this milestone alone.